KRAS and colorectal carcinoma: Tetrac effectively improved the antiproliferative activity of heteronemin through the inactivation of the EGFR/ERK1/2 signaling pathway and induction of antitumor immunity via suppression of PD-L1 expression in HCT-116 cells (KRAS MT CRC).